• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Drugs No Longer in Development

The therapies listed below appear to have had development paused by their sponsors. The reasons for interrupting development can be multiple, such as lack of efficacy (i.e., Phase 2/3 clinical trial sponsored by the company did not meet its primary endpoint), safety concerns, unfavourable risk-benefit profile, insufficient market potential or regulatory setbacks.

This list includes therapies that were in development from approximately 2023 onwards. If you have any questions or concerns, please feel free to contact alliance@als-mnd.org.

AMX0035

Reldesemtiv

Arimoclomol

TUDCA

CuATSM

Primary Sidebar

  • Denis Blais, Canada

    Denis Blais, Canada

  • David Hall, USA

    David Hall, USA

  • Shaleen Latchman, Canada

    Shaleen Latchman, Canada

  • Gisli Jonasson, Iceland

    Gisli Jonasson, Iceland

  • Mauricio Dorin, Argentina

    Mauricio Dorin, Argentina

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Ann Nicol, USA

    Ann Nicol, USA

  • Joy Blakeley, Australia

    Joy Blakeley, Australia

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Erwin Coppejans, Belgium

    Erwin Coppejans, Belgium

  • Mike Rannie, Canada

    Mike Rannie, Canada

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Armando González Gómez, Colombia

    Armando González Gómez, Colombia

  • Anna Barrow, UK

    Anna Barrow, UK

  • Mikey Stone, ALS

    Mikey Stone, ALS

  • Timmy, Belgium

    Timmy, Belgium

  • Anita Forte, USA

    Anita Forte, USA

  • Wiebke Braach, Germany

    Wiebke Braach, Germany

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • David Solomon, UK

    David Solomon, UK

  • Tso-Ta Huang, Taiwan

    Tso-Ta Huang, Taiwan

  • Monica Soriano, Argentina

    Monica Soriano, Argentina

  • Seckin McGuirk, England

    Seckin McGuirk, England

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Graham Johnson, Australia

    Graham Johnson, Australia

  • Lineke Veenstra, Netherlands

    Lineke Veenstra, Netherlands

  • David Bishop, UK

    David Bishop, UK

  • Dick Dayton, USA

    Dick Dayton, USA

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • John Sweeney, USA

    John Sweeney, USA

  • Ismail Gokcek, Turkey

    Ismail Gokcek, Turkey
    ismail_gokcek_alsmnd_tr

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Ada Garrido Benavidez, Mexico

    Ada Garrido Benavidez, Mexico

  • Karl Hughes, Ireland

    Karl Hughes, Ireland

  • Horacio Fritzer, Argentina

    Horacio Fritzer, Argentina

  • Angelique van der Lit-van Veldhuizen, Netherlands

    Angelique van der Lit-van Veldhuizen, Netherlands

  • Fabio Carvalho, Brazil

    Fabio Carvalho, Brazil

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Jay Epstein, USA

    Jay Epstein, USA

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Jo Knowlton, Scotland

    Jo Knowlton, Scotland

  • Eddy LeFrançois, Canada

    Eddy LeFrançois, Canada

  • Glen Victor Peters, Australia

    Glen Victor Peters, Australia

  • Anderson Custodio Pinto, Brazil

    Anderson Custodio Pinto, Brazil

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Ian Roberts, Australia

    Ian Roberts, Australia

  • Sam Hayden-Harler, UK

    Sam Hayden-Harler, UK

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login